Medicexchange.com News

Archive for the ‘Specialities’ Category

For patients with inoperable liver cancer that are not responding to chemotherapy, 90Y Radioembolization is a feasible solution: study corroborates

 

The study was contributed by: Riad Salem, M.D., M.B.A., a professor of radiology and director of interventional oncology at Northwestern University in Chicago; and Daniel E. Wertman Jr., M.D., co-chief of interventional radiology and an assistant professor of clinical radiology at the Indiana University School of Medicine in Indianapolis.

Liver tumors get blood supply through hepatic artery, while liver draws most through the portal vein, and 90Y radioembolization takes advantage of the very same. (Courtesy: RSNA)

Microspheres cover the tumors, and since they focus at the tumors, limited damage to neighboring normal tissue occurs.

About 151 patients with mean age of 63 years were examined through that reported with metastatic cancer, with spread to their livers, not responding to chemotherapy. (vide: Oncology)

Patients were passed through (from 2006-2010) two 90Y radioembolization sessions, with a time gap of five weeks; each of them received about 120 gy, and researchers tracked their progress for nine months, and every six months then after.

About 96% of events associated to the treatment were mild; no unanticipated/adverse events were observed; survival rate varied per cancer origin; in comparison to patients with colorectal cancer, patients that had neuroendocrine tumors endured well.

Comprehensive treatment plan is vital for the success of 90Y radioembolization; utilization of CT for tumor volume and angiography for blood supply to the tumor is fundamental; for patients with dismal hope, radioembolization can bring in fresh hope.

Surgery can be first option for only 10-20% of hepatocellular carcinomas; without surgical procedures, the disease will become fatal for the patients.

90Y radioembolization delay off liver breakdown, and enhance quality of life, of the patients; it is even plausible for patients for liver improvement that are up for liver transplants.

Through number of prospective trials, 90Y radioembolization has been considered apt for metastatic disease in the liver, when chemotherapy has fallen through; the treatment is secure, least toxic than other, and effective.

The treatment in combination with systemic agents show better response rates, and enhanced survival rate; further study is on of 90Y with other care standards.

The new X-ray technology is feasible for melanoma and other grave skin cancers

 

After robust x-ray technology for hepatitis, bird/swine flu, Alzheimer’s disorder, autoimmune disorders and related, now the U.S. Department of Energy’s (DOE’s) national laboratories has come up with novel drug treatment, for malignant melanoma, a grave form of skin cancer. (Courtesy: U.S. Department of Energy)

Zelboraf (vemurafenib) has recently been approved by Food and Drug Administration. In demonstrating the structures of morbid and disease-causing molecules at their primary level, these light sources let scientists to recommend possible new treatments.

The technology has shown great hope for grave skin cancers (vide: Oncology); increased amount of medical researchers and drug discovery companies rely on X-ray facilities at the DOE national laboratories for to investigate reasons of particular disorder, and formulate new treatments.

Research investigators from Plexxikon Inc. (which is into drug discovery) that formulated this melanoma treatment utilized X-ray light sources at following national laboratories (Lawrence Berkeley National Laboratory, SLAC National Accelerator Laboratory and Argonne National Laboratory) to decide 3-dimensional protein structure of a mutated enzyme that communicates information to melanoma cancer cells to propagate, in an uncontrolled manner, and macromolecular X-ray crystallography (technique) was utilized for the drug to prevent this enzyme.

Zelboraf (vemurafenib) was found productive in clinical trials; drug discovery from Plexxikon is severely dependent on gearing the power of X-ray crystallography; the role of the U.S. Department of Energy in development of vemurafenib is profound, states Gideon Bollag (Senior Vice President, for Research at Plexxikon).

The Department of Energy back up five of these innovative X-ray light sources (all big installations) that generate accurate, high-intensity X-ray beams; and Scientists across the globe are utilizing the user facilities at the DOE’s national laboratories for discoveries in a widespread range.

For more on Vemurafenib and other related threads, stay tuned with MedicExchange!

About 17% of nurses at outpatient chemotherapy infusion centers are prone to toxic drugs they deliver: study reports

 

This recent study from the University of Michigan Comprehensive Cancer Center found that toxic drugs had adverse effect on eyes and skin of the nurses that work daily with it.

The study was led by Christopher Friese, R.N., Ph.D., assistant professor, the University of Michigan School of Nursing.

About 84% of chemotherapy is done in outpatient care centers, mostly by nurses; the study examined 1,339 oncology nurses that did not work in inpatient settings. (Courtesy: University of Michigan Health System)

Any involuntary exposure to eyes/skin are as grave as needlestick injury; researcher states that needlestick injuries are rare, and in any such cases, nurses can instantly go for assessment and preventive treatment; but there is no such for chemotherapy exposure, to direct it to any health effect.

National Institute for Occupational Safety and Health and related have already set ‘rule of thumb’ for chemotherapy drug administration, but these rules are not obligatory. Friese said, the guidelines comprise – suggestions for using glove, gowns and other preventive gear while managing with chemotherapy drugs.

Nurses from University of Michigan School of Nursing did not partake in the study, as the University of Michigan Comprehensive Cancer Center follows up strictly on these guidelines and standards.

The study found that medical practices that had more staff and resources had fewer exposures, of that kind; same was that with practices where more than two nurses were required for chemotherapy order verification, as part of recommended guidelines.

Involuntary chemotherapy exposure can adversely affect the nervous system, weaken the reproductive system, and present prospective risk of blood cancers.

The researcher cooperated in the study with the University of Michigan School of Nursing’s occupational health nursing program on training nurses for protection against possible environmental hazards and job-based injuries, at the workplace.

On the concluding note, Friese said that both patient and employee safety is to be ensured through staff education, and abidance to national safety guidelines.

pneumo-64-MDCT proves feasible for esophageal wall thickening, and to stage esophageal cancer

 

The medical research was contributed by Marina Ulla, Ernestina María José Gentile, Demetrio Cavadas, Ezequiel Levy Yeyati, Laura Frank, Javier Ithurralde Argerich and Ricardo Garcia Mónaco from Department of Radiology and Surgery; Hospital Italiano, Universidad de Buenos Aires, Argentina. (Courtesy: SpringerLink)

Early identification and precise staging of esophageal cancer are fundamental for therapeutic schemes.

CT, PET, and endoscopic ultrasound have been well utilized, individually and otherwise in combination for pre-operative staging of esophageal cancer.

Delineation of anatomic location of tumor facilitate for surgical plan; PET and endoscopic ultrasound are potent, but neither support for surgical plans.

Computed tomography has restrictions for hollow organs, with shortage of lumen distension; optical esophageal distension is beneficial to surmount these restraints; the possible disadvantage is vital at gastro-esophageal junction (GE junction), particularly difficult to assess.

For optimal tumor visualization in the GE junction and esophageal wall, the team developed a method – pneumo-64-MDCT.

Maximum lumen distension is achieved that portrays the thickened regions in association to the regular esophageal wall.

The team executed 200 studies through this method, and it showed beneficial, secure and precise for esophageal wall thickening, and for to stage esophageal cancer.

The extra stomach distension led to a sufficient explanation of lower and upper regions of the lesion in tumors situated in the gastro-esophageal junction; this in turn was beneficial to fabricate surgical approach.

11C-4DST PET is feasible for brain tumor imaging; pharmacological safety and dosimetry are reasonable at the dose necessary for suitable PET images.

 

The medical research study was contributed by Jun Toyohara (Positron Medical Center, Tokyo Metropolitan Institute of Gerontology) and associates. (Courtesy: The Journal of Nuclear Medicine)

Lately, the team developed [methyl-11C]4′-thiothymidine (11C-4DST) as an in vivo cell propagation marker; the research study was to decide radiation dosimetry, security, allocation/distribution and primary brain tumor imaging of 11C-4DST in humans.

Radiation dosimetry and multi-organ biodistribution of 11C-4DST were evaluated in 3 subjects that passed through 2-h whole-body PET imaging.

OLINDA program was utilized for radiation dosimetry; about 6 patients (brain tumor) passed through dynamic 11C-4DST scans with arterial blood sampling; the patients were even assessed with 11C-methionine PET; plasma substance and urine samples were construed through liquid chromatography.

Gadolinium-enhanced T1-weighted MRI was utilized for perturbation of blood-brain obstruction in tumor tissue.

No adverse events were reported during study phase with any of subjects; 11C-4DST PET showed selective consumption in the bone marrow; high-level uptake was observed in liver.

Urinary bladder wall has had highest absorbed dose; the appraised effective dose for 11C-4DST was 4.2 μSv/MBq.

11C-4DST demonstrated slight uptake in normal tissues (brain), ensuing in low background activity for tumor imaging.

In comparison, 11C-4DST PET showed swift uptake in truculent tumor masses; no sign of 11C-4DST was found in clinically fixed disorder in which 11C-methionine uptake was high.

The allocation pattern of 11C-methionine in tumor sections was not always similar to that of 11C-4DST; examination of plasma samples through liquid chromatography showed that more than 60% of radioactivity was present as unaltered 11C-4DST at 20 min.

Conclusion: small group patient study – primary findings show that 11C-4DST PET is plausible for brain tumor imaging; pharmacological safety and dosimetry were reasonable at the dose necessary for suitable PET images.

Fine localization of 124I-huA33 in colorectal cancer, with no considerable toxicity has been found;

PET-deduced 124I concentrations demonstrated good agreement with other samples, and confirmed quantitative precision of 124I-huA33 PET.

 

The medical research was contributed by Jorge A. Carrasquillo and associates from various departments of Memorial Sloan-Kettering Cancer Center, New York. (Courtesy: The Journal of Nuclear Medicine)

Humanized A33 (huA33) is a monoclonal antibody that is present in normal bowel and above 95% of colorectal cancers. The research team tried PET to assess 124I huA33 focusing bio-distribution, and security in patients with colorectal cancer. They even decided the bio-distribution of 124I-huA33, when higher dose of human intravenous IgG (IVIG) was administered to control the Fc receptor, or when 124I-huA33 was administered through hepatic arterial infusion (HAI).

About 25 patients with primary/metastatic colorectal cancer encompassed the study; 19 had resection. Patients received a median of 343 MBq and 10 mg of 124I-humanized A33.

19 had intravenous antibody administration, 6 through hepatic arterial infusion; 5 received human intravenous IgG.

About 11 patients showed up with 10 primary tumors (vide: Oncology); median concentration (primary colon tumors) was 0.016% instilled dose/gram, in comparison with normal colon that had 0.004%.

Notable uptake in bowel hampered tumor recognition in some patients; patients receiving human intravenous IgG had a considerably shorter serum half-time (corroborated through, Pharmacokinetics).

No deviation could be established in clearance rates amid following groups – IVIG, HAI, intravenous; same was that for maximum serum concentration/volume of distribution, serum region under the curve.

Weak concentration of human–antihuman antibodies were found in 6 patients; no considerable toxicities/side effects were related with huA33.

Conclusion: Good determination/localization of 124I-huA33 in colorectal cancer, with no considerable perniciousness has been found. PET-deduced 124I concentrations showed good agreement with other samples, and confirmed quantitative precision of 124I-huA33 PET; no clinically vital changes in blood clearance were brought about by human intravenous IgG.

Thermal ablations are possible options for minimally invasive therapy to scorch the infected tissue

 

Lung malignancies are frequently treated with surgery – whether primary, or secondary; many patients are unable for surgical procedures due to old age, or concurrent health conditions. (Courtesy: RSNA)

Options to surgical procedure for localized disorder comprise – radiation therapy and image-guided thermal ablation.

The latter involves utilization of needlelike applicators, which through image guided process are placed straightly into tumors. (vide: Oncology)

Thermal ablation makes use of either heat/cold to put down lung tumor cells; in case of radio-frequency ablation, heat is commonly used – feasible for tumors of kidney, lung, bone and liver, to name a few.

The particular modalities of microwave, laser ablation, and cryoablation have diverse clinical evidences for lung malignancies – both primary and secondary.

For more on the thread and related, stay tuned with MedicExchange!

Gene therapy is secure for grave form of brain cancer, even when merged with radiation therapy – clinical trial report states

 

The innovative treatment makes use of an adenovirus vector (AdV-tk); it is applied in the operating room, after taking off brain tumors, viz. glioblastoma multiforme. (Courtesy: Ohio State University Comprehensive Cancer Center; Journal of Clinical Oncology)

The treatment might even incite reaction against the tumor; this is first ever approach of gene therapy with radiation for newly identified glioblastoma; grave concerns related to toxicity were there with combination of both the treatments, but the findings are positive.

About 13,000 die annually due to Glioblastomas in the U.S.; average survival of grave/most common Glioblastoma multiforme is 15 months post diagnosis.

Due to typical migration of cancer cells to neighboring brain tissues, tumors recur frequently; the study evaluates immunogene therapy, which is devised to kill undiscovered cancer cells, and impede recurrence. (vide: Oncology)

About 10 patients with glioblastoma multiforme, and 2 with anaplastic astrocytoma involved in the study; the routine follows – after removal of tumor, the tumor bed is injected with 1 milliliter of a solution comprising the AdV-tk vector; it carries gene from herpes simplex virus, for thymidine kinase; infected cells with the vector start making the enzyme. Patients take anti-herpes virus drug for about 14 days; within cancer cells – herpes thymidine kinase transform valacyclovir into DNA building blocks.

Radiotherapy begins midway through the pattern of valacyclovir (drug); DNA in the infected cells get damaged by radiation – it then tries to mend it, through toxic valacyclovir building blocks.

More to enhanced survival, studies disclosed a considerable rise in amount of T lymphocytes in the tumors; this indicates that gene therapy incited an immune reaction against tumor. In cancer immunogene therapy, cancer cells are genetically manipulated to incite a immune reaction against the tumor.

With supportive results from phase 2 efficacy trial, next step will be to equate the therapy with existent standard of care, researchers conclude.

Irrespective of dubiousness of relevant use of radioactive iodine for varied stages of thyroid cancer, its utility increased during 1990-2008 with cancer patients – of different tumor sizes: study reports

 

Diverse fluctuation was observed with ‘radioactive iodine’ treatment in hospitals; every year, more than 40,000 people get diagnosed for thyroid cancer in the US, and thyroidectomy is standard for most well-marked thyroid cancer cases. (Courtesy: The Journal of the American Medical Association)

Radioactive iodine, is frequently administered after complete thyroidectomy to ascertain obliteration of residual thyroid tissue, and to treat patients with seeable, not able to be operated, iodine-avid metastases.

Earlier studies disclose reduced tumor and higher survival rate in patients, with advanced/well-distinguished thyroid cancer (vide: oncology) that were treated with radioactive iodine.

Researchers [Megan R. Haymart, M.D. (University of Michigan, Ann Arbor, Michigan) and associates] evaluated developments in practice patterns with usage of radioactive iodine subsequent to thyroidectomy, and investigated varied levels of radioactive iodine usage in hospitals.

The study encompassed about 189,219 patients, with well-marked thyroid cancer that were treated at 981 hospitals related with the National Cancer Database, between 1990-2008. Considerable increase across all tumor sizes revealed out, of thyroid-cancer patients that received radioactive iodine after complete thyroidectomy, during this period.

About 40.4% patients received radioactive iodine in 1990; it shot to 56.0% in 2008. Younger patients and other without comorbidity were related to small/higher probability of receiving radioactive iodine, post total thyroidectomy, research suggests.

Black Americans (female) and patients devoid of insurance plans were related to having considerably lower chances of receiving radioactive iodine; statistically significant deviation in radioactive iodine use amid American Joint Committee on varied cancer stages, even established out.

With respect to volume of thyroid cancer cases, likelihood of radioactive iodine use increased – hospital case volume study report; to control healthcare cost and hinder under/over treatment of disorders, radioactive iodine usage should be clearly defined per severity of the disease, conclude research authors.

Serial PET scans, through peculiar estrogen-containing isotope found viable for relative effectiveness of estrogen-blocking/depleting therapy in metastatic breast cancer cases, substantiates Seattle Cancer Care Alliance.

 

The study was contributed by: Hannah Linden, M.D.; David Mankoff, M.D.; Jeanne Link, M.D., and Kenneth Krohn, M.D., at the SCCA, and UW; and Brenda Kurland (Statistician, Fred Hutchinson Cancer Research Center).

PET scans – prior, on and after hormonal therapy affirmed the potency of estrogen-receptor-blocking drugs over estrogen-depleting therapies to withhold estrogen receptor in cancer cells; tamoxifen has even been substantiated over fulvestrant in to block estrogen.

Researchers (Linden & the team) evaluated territorial estrogen-receptor blocking/binding through PET scans with 18F-Fluoroestradiol (FES), before, and on discourse with aromatase inhibitors, fulvestrant, and tamoxifen in about 30 patients with breast cancer (vide: oncology) spread to the bones.

Tumor FES uptake waned in patients that took estrogen-receptor blockers, in comparison to others that had taken estrogen-depleting aromatase inhibitors; of both the studies, the rate of all over tumor blockade was highest sticking to use of fulvestrant, in contrast to tamoxifen.

Results suggest FES PET for effective visualization of in vivo activity of endocrine therapy; the technology can be utilized in drug development to gauge effectiveness at purposeful therapeutic targets, and to improve dosing/selection for agents. Moreover, pharmacodynamic imaging is feasible for therapeutic selection, and to evaluate/predict response to estrogen-receptor directed therapy.

(Courtesy: Journal of American Association for Cancer Research)